CA3154321A1 - Tak-925 for use in treating narcolepsy - Google Patents

Tak-925 for use in treating narcolepsy Download PDF

Info

Publication number
CA3154321A1
CA3154321A1 CA3154321A CA3154321A CA3154321A1 CA 3154321 A1 CA3154321 A1 CA 3154321A1 CA 3154321 A CA3154321 A CA 3154321A CA 3154321 A CA3154321 A CA 3154321A CA 3154321 A1 CA3154321 A1 CA 3154321A1
Authority
CA
Canada
Prior art keywords
compound
subject
administration
plasma concentration
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3154321A
Other languages
English (en)
French (fr)
Inventor
Deborah Hartman
Rebecca Evans
Helene FAESSEL
Shinichiro Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA3154321A1 publication Critical patent/CA3154321A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3154321A 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy Pending CA3154321A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900298P 2019-09-13 2019-09-13
US62/900,298 2019-09-13
US202063031686P 2020-05-29 2020-05-29
US63/031,686 2020-05-29
PCT/IB2020/058483 WO2021048822A1 (en) 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy

Publications (1)

Publication Number Publication Date
CA3154321A1 true CA3154321A1 (en) 2021-03-18

Family

ID=72560858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3154321A Pending CA3154321A1 (en) 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy

Country Status (11)

Country Link
US (1) US20220339143A1 (https=)
EP (1) EP4028004A1 (https=)
JP (1) JP2022547711A (https=)
KR (1) KR20220062012A (https=)
CN (1) CN114980892A (https=)
AU (1) AU2020346456A1 (https=)
BR (1) BR112022004587A2 (https=)
CA (1) CA3154321A1 (https=)
CO (1) CO2022004596A2 (https=)
MX (1) MX2022003018A (https=)
WO (1) WO2021048822A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220062361A (ko) * 2019-09-13 2022-05-16 다케다 야쿠힌 고교 가부시키가이샤 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
AU2021205892B2 (en) 2020-01-10 2026-04-23 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US20240165092A1 (en) * 2021-04-02 2024-05-23 Takeda Pharmaceutical Limited Company Use of an orexin 2 receptor agonist for post operation recovery
IL316468A (en) 2022-04-22 2024-12-01 Teijin Pharma Ltd The aftermath of oxazepine
WO2024075825A1 (ja) 2022-10-07 2024-04-11 キッセイ薬品工業株式会社 シクロペンタン化合物
EP4611745A1 (en) * 2022-10-31 2025-09-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
TW202535890A (zh) 2023-10-20 2025-09-16 日商帝人製藥股份有限公司 氧氮呯衍生物之結晶或其溶劑合物之結晶
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2025229493A1 (en) * 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
MX376164B (es) * 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
WO2016201373A1 (en) * 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
LT3984994T (lt) * 2016-02-04 2024-10-10 Takeda Pharmaceutical Company Limited Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti

Also Published As

Publication number Publication date
JP2022547711A (ja) 2022-11-15
EP4028004A1 (en) 2022-07-20
CN114980892A (zh) 2022-08-30
KR20220062012A (ko) 2022-05-13
WO2021048822A1 (en) 2021-03-18
BR112022004587A2 (pt) 2022-06-14
US20220339143A1 (en) 2022-10-27
AU2020346456A1 (en) 2022-04-14
MX2022003018A (es) 2022-06-14
CO2022004596A2 (es) 2022-08-30

Similar Documents

Publication Publication Date Title
CA3154321A1 (en) Tak-925 for use in treating narcolepsy
US20220331303A1 (en) Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
TWI419681B (zh) 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途
TW201105677A (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
JP2003524613A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2003521470A (ja) ベンラファキシンの誘導体とその調製および使用方法
EP0276536B1 (en) Use of buspirone for the improvement of short term memory
US20250326714A1 (en) Pure forms of crystalline aticaprant
US20230150966A1 (en) Isotopically enriched 3,4-methylenedioxy-n-ethylamphetamine (mde) and stereoisomers thereof
AU2004226827B2 (en) Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
UA77000C2 (en) Crystalline form of hydroxynorephedrine derivative
AU2022234744B2 (en) Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
TW202543580A (zh) 於側鏈具有環狀基之胺甲醯基脂質、其脂質奈米粒子及其醫藥組成物
US10420773B2 (en) Methods of treating developmental disorders and/or seizure disorders with etifoxine
EP3400940B1 (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
JP2015509931A (ja) 医薬的な組み合わせ
JP2026510479A (ja) オレキシン２型受容体作動薬の投与
EP4414029A2 (en) Methods of use for kv7 channel activators
CA3250678A1 (en) TREATMENT OF NEUROLOGICAL DISORDERS
US20090306050A1 (en) Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
US20240025852A1 (en) T-type calcium channel modulators and methods of use thereof
US20080261955A1 (en) Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
PL189822B1 (pl) Zastosowanie (+)-5-(2,3-dihydrobenzofuran-7-ylo)-7-hydroksy-3-metylo-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepiny lub jej farmaceutycznie dopuszczalnej soli do wytwarzania kompozycji farmaceutycznej
HK40113570A (en) Methods of use for kv7 channel activators
WO2025038420A1 (en) Kappa opioid receptor antagonist and methods and products related thereto

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260304